Lymphoma

Investigators on the BRUIN trial reported impressive response rates across multiple B-cell malignancies with the use of the Bruton tyrosine kinase inhibitor LOXO-305, especially in those with heavily pretreated mantle cell lymphoma.

An expert in the treatment of diffuse large B-cell lymphoma explained some of the exciting advances in treatment and hypothesized what comes next after the 2020 ASH Annual Meeting & Exposition.

Ghobadi expressed caution about interpreting efficacy data from a phase 1 pilot study presented at the 2020 ASH Annual Meeting.

The preliminary findings of the extension arm of the phase 1b/2 GO29365 study confirmed the benefits and tolerability of polatuzumab vedotin plus bendamustine and rituximab for patients with diffuse large B-cell lymphoma.

Ghobadi detailed the next steps needed to build on the results of a study presented at the 2020 American Society of Hematology Annual Meeting & Exposition.

Extended follow up and preliminary findings from an extension cohort of the GO29365 study of polatuzumab vedotin (Polivy) for patients with diffuse large B-cell lymphoma confirmed earlier reports of efficacy and safety, and demonstrated continued deepening responses.

Ghobadi explained an interesting correlation found in the results of his study presented at the 2020 ASH Annual Meeting & Exposition.

The ongoing GO29365 study of combination regimens containing polatuzumab vedotin (Polivy) for patients with relapsed or refractory diffuse large B-cell lymphoma added an additional 106 patients to confirm preliminary findings of safety and efficacy.

Patients with aggressive lymphomas had a sharp increase in quality of life from time of diagnosis until 1 year later.

A recent study found a difference in preference when it came to the administration of rituximab in patients with blood cancer.

Research from a pilot trial presented at the 2020 American Society of Hematology (ASH) Annual Meeting found above average complete response and disease-free survival rates for patients with DLBCL.

The preliminary findings of the extension arm of the phase 2 GO29365 study confirmed the benefits and tolerability of polatuzumab vedotin (Polivy) plus bendamustine (Bendeka) and rituximab (Rituxan) for patients with diffuse large B cell lymphoma.

A phase 1 trial found that MEDI-570 demonstrated clinical activity with durable responses, as well as acceptable safety and tolerability in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma.

Research presented at the 2020 ASH Annual Meeting may have found an alternative path forward for patients who do not respond to immunotherapy treatment for large B-cell lymphomas.

The lymphoma expert spoke about the research being presented at the 2020 ASH Annual Meeting and what he believes has the potential to be most influential for treating this patient population.

A novel ROR1-targeted antibody-drug conjugate, VLS-101, demonstrated encouraging clinical efficacy, consistent pharmacokinetics, and a favorable safety profile in patients with heavily pretreated mantle cell lymphoma and diffuse large B-cell lymphoma.

The CAR T-cell therapy axicabtagene ciloleucel demonstrated long-term disease control with rapid responses and robust CAR T-cell expansion among patients with refractory large B-cell lymphoma.

The CAR T-cell therapy elicited a 92% ORR, with high rates of durable responses in patients with indolent non-Hodgkin lymphoma.

A novel CD20xCD3 bispecific antibody, odronextamab, continues to show intriguing antitumor activity and an acceptable safety profile in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, including those who have previously received chimeric antigen receptor T-cell therapy.

Regardless of age, Selinexor induced a clinical benefit in patients with relapsed/refractory diffuse large B-cell lymphoma.

A study presented at ASTRO suggested that response-based consolidation involved-field radiation therapy appears to be a safe and effective standard of care for a cohort of pediatric patients with high-risk classical Hodgkin lymphoma.

The FDA has accepted and granted priority review to the biologics license application (BLA) for loncastuximab tesirine (Lonca) for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

The priority review of the biologics license application for lisocabtagene maraleucel (liso-cel) for the treatment of adults with relapsed or refractory large B-cell lymphoma after at least 2 prior therapies will not be completed by the prescription drug user fee act date.

In June 2020, the FDA approved tazemetostat (Tazverik) for 2 distinct follicular lymphoma indications based on overall response rate and duration of response observed in phase 2 clinical trial cohorts of patients with follicular lymphoma with EZH2 mutations and wild-type EZH2.

Cycle 3 of the FLASH study reported that patients taking SGX301 to treat cutaneous t-cell lymphoma saw improved responses and maintained a positive safety profile.

The study established 4 cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) alone as the new standard approach for the majority of patients with limited-stage diffuse large B-cell lymphoma.

This phase 1 study found that vorinostat (Zolinza) in combination with either sirolimus (Rapamune) or everolimus (Afinitor) demonstrated clinical efficacy in patients with relapsed and/or refractory Hodgkin lymphoma and warrants further investigation.

The FDA approved an expanded label for pembrolizumab (Keytruda) as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma.

The study is evaluating copanlisib (Aliqopa) in combination with rituximab (Rituxan) in patients with indolent non-Hodgkin’s lymphoma who have relapsed after 1 or more prior lines of rituximab-containing therapy.

Researchers identified molecular and cellular characteristics of anti-CD19 CAR T-cell infusion products associated with how patients with large B-cell lymphoma respond to treatment and experience adverse events.